Additionally, our analysis included all lung cancer patients from the TCGA database (n = 1411; 478 low vs. 933 high VPS18), whereas Niu et al. focused exclusively on patients with lung adenocarcinomas (n = 504; 367 low vs. 137 high VPS18). This evidence concerns the gene VPS18 and lung adenocarcinoma.